Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tatevik Ohanyan

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
JAMA Dermatology|January 31, 2014
Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticariaMartin Metz, Tatevik Ohanyan, Martin K Church, et al.
Journal of Dermatological Science|September 25, 2013
Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysisMartin Metz, Tatevik Ohanyan, Martin K Church, et al.
The Journal of Allergy and Clinical Immunology|October 13, 2018
Real-life treatment of cholinergic urticaria with omalizumabSabine Altrichter, Mati Chuamanochan, Henriette Knoth, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 8, 2019
The response to treatment in chronic spontaneous urticaria depends on how it is measuredKarsten Weller, Martin K Church, Martin Metz, et al.
Acta Dermato-Venereologica|August 31, 2017
Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical AprepitantTatevik Ohanyan, Nicole Schoepke, Stefan Eirefelt, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 13, 2017
The Urticaria Activity Score-Validity, Reliability, and ResponsivenessTomasz Hawro, Tatevik Ohanyan, Nicole Schoepke, et al.
The Journal of Allergy and Clinical Immunology|June 20, 2017
Responsiveness and minimal important difference of the urticaria control testTatevik Ohanyan, Nicole Schoepke, Bediha Bolukbasi, et al.
Allergy|August 5, 2018
Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumabKarsten Weller, Tatevik Ohanyan, Tomasz Hawro, et al.
The Journal of Allergy and Clinical Immunology|November 14, 2016
Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticariaJanine Gericke, Martin Metz, Tatevik Ohanyan, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
JAMA Dermatology|January 31, 2014
Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticariaMartin Metz, Tatevik Ohanyan, Martin K Church, et al.
Journal of Dermatological Science|September 25, 2013
Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysisMartin Metz, Tatevik Ohanyan, Martin K Church, et al.
The Journal of Allergy and Clinical Immunology|October 13, 2018
Real-life treatment of cholinergic urticaria with omalizumabSabine Altrichter, Mati Chuamanochan, Henriette Knoth, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 8, 2019
The response to treatment in chronic spontaneous urticaria depends on how it is measuredKarsten Weller, Martin K Church, Martin Metz, et al.
Acta Dermato-Venereologica|August 31, 2017
Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical AprepitantTatevik Ohanyan, Nicole Schoepke, Stefan Eirefelt, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 13, 2017
The Urticaria Activity Score-Validity, Reliability, and ResponsivenessTomasz Hawro, Tatevik Ohanyan, Nicole Schoepke, et al.
The Journal of Allergy and Clinical Immunology|June 20, 2017
Responsiveness and minimal important difference of the urticaria control testTatevik Ohanyan, Nicole Schoepke, Bediha Bolukbasi, et al.
Allergy|August 5, 2018
Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumabKarsten Weller, Tatevik Ohanyan, Tomasz Hawro, et al.
The Journal of Allergy and Clinical Immunology|November 14, 2016
Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticariaJanine Gericke, Martin Metz, Tatevik Ohanyan, et al.
Pageof 1